Reaction Biology Corporation acquired vivoPharm, LLC from Vyant Bio, Inc. (NasdaqCM:VYNT) for approximately $6 million on November 2, 2022. The purchase price for this transaction is $5.5 million in an upfront cash payment, subject to customary adjustments for working capital, closing cash, indebtedness and transaction expenses. After these closing adjustments were reflected, $5.5 million was paid at closing. Luke Laumann of White & Case LLP acted as legal advisor to Reaction Biology Corporation. Alan Wovsaniker of Lowenstein Sandler LLP acted as legal advisor to Vyant Bio, Inc. Colliers Securities LLC and Lake Street Capital Markets, LLC acted as financial advisor to Vyant Bio, Inc.

Reaction Biology Corporation completed the acquisition of vivoPharm, LLC from Vyant Bio, Inc. (NasdaqCM:VYNT) on November 2, 2022.